Carglumic Acid Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Carglumic Acid Market is Segmented by Dosage Form (Orally Disintegrating Tablets, Dispersible Tablets, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce Channel), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Carglumic Acid Market Size

Compare market size and growth of Carglumic Acid Market with other markets in Healthcare Industry

Carglumic Acid Market Analysis

The Carglumic Acid Market is expected to register a CAGR of 7.2% during the forecast period.

COVID-19 brought a high infection rate among the population across the globe.The medical emergency known as hyperammonemia results in cerebral edema and neurologic impairment. Due to hyperammonemia from a disseminated cryptococcal infection, respiratory distress syndrome in COVID-19 patients may be the cause of such an infection.A rare genetic condition characterized by a lack of N-acetylglutamate synthase (NAGS) can be treated with the orphan medication carglumic acid, which aids in converting ammonia into urea in patients. This condition is creating a demand for carglumic acid medications for patients suffering from COVID-19 infections. Due to a deficit in the hepatic enzyme NAGS, it was utilized as a supplementary therapy for the treatment of acute hyperammonemia and as a maintenance therapy for chronic hyperammonemia. Hence, the COVID-19 pandemic significantly impacted the market.

The main things that are driving the growth of the carglumic acid market are the rise in cancers caused by drinking, smoking, and being inactive, as well as the rise in metabolic disorders like hepatic encephalopathy, Reye's syndrome, and cirrhosis around the world.WHO's key facts, which were last updated in May 2022, say that drinking too much can cause more than 200 diseases and injuries.According to the same source as above, alcohol-related disabilities caused 5.1% of the world's disease and injury burden in 2022.The amount of ammonia in the blood rises as people drink more alcohol. Carglumic acid is used and prescribed to lower the amount of ammonia in the blood.This is expected to drive the market.

In the same way, more people smoking and the problems that come with smoking are likely to increase the use of carglumic acid and help the market grow.For instance, according to the Office on Smoking and Health and the Chronic Disease Center (NCCDPHP), whose data was updated in March 2022, nearly 13 of every 100 United States adults aged 18 years or older (12.5%) smoked cigarettes in 2020. This means an estimated 30.8 million adults in the United States currently smoke cigarettes. More than 16 million Americans live with a smoking-related disease. Therefore, the smoking-related disease burden is anticipated to create demand for arglumic acid products, further fueling the market's growth.

In addition, hepatic encephalopathy (HE) is a nervous system disorder that is caused by severe liver disease and is often treated with carglumic acid. The number of people with covert hepatic encephalopathy (CHE) goes up to 54% when minimal hepatic encephalopathy (MHE) is found, according to an article in the Clinical Gastroenterology and Hepatology journal from August 2022.This burden of HE is expected to drive market growth. Additionally, according to the National Institute of Neurological Disorders and Stroke (NINDS) data published in February 2022, an estimated two children per year in the United States develop Reye's syndrome. This is expected to accumulate ammonia in the blood and thereby increase growth. Also, carglumic acid has shown potential for anti-tumor activity in breast cancer, along with various applications in cosmetics and chemicals, which are expected to fuel the global carglumic acid market during the forecast period.

But the market isn't growing as fast as it could because there are more problems in the development stage, patented products are expensive, and carglumic acid medicines can have serious side effects.

Carglumic Acid Industry Overview

The global carboxylic acid market is moderately competitive and consists of several major players. In terms of market revenue, a few prominent players are currently dominating the market and are applying various strategies, like acquiring products or other companies, to consolidate their market positions across the globe. Some of the companies that are currently dominating the market are Apothecon Pharmaceuticals Pvt. Ltd., Manus Aktteva Biopharma LLP, Recordati Rare Diseases Inc., Dipharma Francis S.r.l., and Civentichem LLC, among others.

Carglumic Acid Market Leaders

  1. Apothecon Pharmaceuticals Pvt. Ltd

  2. Manus Aktteva Biopharma LLP

  3. Recordati Rare Diseases Inc

  4. Civentichem LLC

  5. Dipharma Francis S.r.l

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF

Carglumic Acid Market News

  • December 2021: Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc commercially launched Carglumic Acid tablets. The product is expected to be marketed by Eton Pharmaceuticals and is the first and only USFDA-approved generic version of Carbaglu.
  • January 2021: Recordati Rare Diseases Inc. received approval from the USFDA for a new indication for CARBAGLU (carglumic acid) tablets 200mg as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) in pediatric and adult patients.

Carglumic Acid Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definitions
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Prevalence of N-acetylglutamate Synthase (NAGS) Syndrome and Cancer Cases
    • 4.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA
  • 4.3 Market Restraints
    • 4.3.1 Severe Adverse Effects Associated with Carglumic Acid Medication
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Dosage Form
    • 5.1.1 Orally Disintegrating Tablets
    • 5.1.2 Dispersible Tablets
    • 5.1.3 Other Dosage Forms
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 E-Commerce Channel
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Apothecon Pharmaceuticals Pvt Ltd
    • 6.1.2 Manus Aktteva Biopharma LLP
    • 6.1.3 Recordati Rare Diseases Inc
    • 6.1.4 Dipharma Francis S r l
    • 6.1.5 Civentichem LLC
    • 6.1.6 NURAY CHEMICALS
    • 6.1.7 NOVITIUM PHARMA LLC
    • 6.1.8 Suven Life Sciences Limited
    • 6.1.9 Biophore India Pharmaceuticals Pvt Ltd.
    • 6.1.10 Rhyme Organics and Chemicals Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Carglumic Acid Industry Segmentation

As per the scope of the report, carglumic acid is an orphan drug used to treat hyperammonemia also known as NAGS Syndrome, a rare genetic disorder that occurs due to the lack of an enzyme called N-acetyl glutamate synthase (NAGS) in the liver, that results in elevated levels of ammonia in the blood causing hyperammonemia. The Carglumic Acid Market is segmented by Dosage Form (Orally Disintegrating Tablets, Dispersible Tablets, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce Channel), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Dosage Form Orally Disintegrating Tablets
Dispersible Tablets
Other Dosage Forms
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
E-Commerce Channel
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Carglumic Acid Market Research FAQs

What is the current Carglumic Acid Market size?

The Carglumic Acid Market is projected to register a CAGR of 7.2% during the forecast period (2025-2030)

Who are the key players in Carglumic Acid Market?

Apothecon Pharmaceuticals Pvt. Ltd, Manus Aktteva Biopharma LLP, Recordati Rare Diseases Inc, Civentichem LLC and Dipharma Francis S.r.l are the major companies operating in the Carglumic Acid Market.

Which is the fastest growing region in Carglumic Acid Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Carglumic Acid Market?

In 2025, the North America accounts for the largest market share in Carglumic Acid Market.

What years does this Carglumic Acid Market cover?

The report covers the Carglumic Acid Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Carglumic Acid Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Carglumic Acid Industry Report

Statistics for the 2025 Carglumic Acid market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Carglumic Acid analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Carglumic Acid Report Snapshots

Carglumic Acid Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)